Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Open accessAbstract
Objective: The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains. Method: Guidelines were developed using the ADAPTE process, which takes advantage of existing guidelines. Six guidelines were identified for adaptation, with recommendations extracted from each. For those specific to the pharmacotherapy of schizophrenia in adults, a working group selected between guidelines and recommendations to create an adapted guideline. Results: Recommendations can be categorized into 6 areas that include 1) first-episode schizophrenia, 2) acute exacerbation, 3) relapse prevention and maintenance treatment, 4) treatment-resistant schizophrenia, 5) clozapine-resistant schizophrenia, and 6) specific symptom domains. For each category, recommendations are made based on the available evidence, which is discussed and linked to other established guidelines. Conclusions: In most cases, evidence-based recommendations are made that can be used to guide current clinical treatment and decision making. Notably, however, there is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recommendations on LAI use in routine care differ between guidelines, and LAI use remains limited despite proved efficacy on long-term patient management.
“yet recommendations on their use in the clinical routine care differ from one guideline to another, and their current use is still limited despite their proved efficacy on long-term patient management [26].”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [26]
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156 · see citing works
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · see citing works
Association Between Duration of Untreated Psychosis and Outcome in Cohorts of First-Episode Patients
Marshall, M., Lewis, S. W., Lockwood, A., Drake, R., Jones, P. B., & Croudace, T. J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,595 · see citing works
The Scottish Intercollegiate Guidelines Network (SIGN)
Miller, J. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020010401 · Cited by 1,546 · see citing works
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327 · see citing works
Perkins, D., Gu, H., Boteva, K., & Lieberman, J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,304 · see citing works
Howes, O. D., McCutcheon, R. A., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050503 · Cited by 1,145 · see citing works
Self-citationLeucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · see citing works
Penttilä, M., Jääskeläinen, E., Hirvonen, N., Isohanni, M., & Miettunen, J. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.127753 · Cited by 716 · see citing works
The Expert Consensus Guideline Series
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 692 · see citing works
Velligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J. L., Carpenter, D., Ross, R., & Docherty, J. P. (2009) · PubMed · Cited by 625 · see citing works
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Fusar-Poli, P., Nelson, B., Valmaggia, L., Yung, A. R., & McGuire, P. K. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs136 · Cited by 589 · see citing works
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585 · see citing works
Witt, K., Dorn, R. A. V., & Fazel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055942 · Cited by 585 · see citing works
Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545 · see citing works
Predictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D. I., Bilder, R. M., GOLDMAN, R. S., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466 · see citing works
Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427 · see citing works
Depression in Schizophrenia: Perspective in the Era of “Atypical” Antipsychotic Agents
Siris, S. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1379 · Cited by 425 · see citing works
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · see citing works
Barnes, T. R. E. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 357 · see citing works
Howes, O. D., Vergunst, F., Gee, S., McGuire, P. K., Kapur, S., & Taylor, D. M. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 355 · see citing works
Shepherd, M., Watt, D., Falloon, I. R. H., & Smeeton, N. (1989) · Psychological Medicine Monograph Supplement · doi:10.1017/s026418010000059x · Cited by 350 · see citing works
Zhang, J., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336 · see citing works
Anchoring the BPRS: an aid to improved reliability.
Woerner, M. G., Mannuzza, S., & Jm, K. (1988) · PubMed · Cited by 331 · see citing works
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 324 · see citing works
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature
Velligan, D. I., Lam, Y.-W. F., Glahn, D. C., Barrett, J. A., Maples, N. J., Ereshefsky, L., & Miller, A. L. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj075 · Cited by 310 · see citing works
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia
Samara, M. T., Dold, M., Gianatsi, M., Nikolakopoulou, A., Helfer, B., Salanti, G., & Leucht, S. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2955 · Cited by 305 · see citing works
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 287 · see citing works
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0270 · Cited by 262 · see citing works
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel‐Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 261 · see citing works
A systematic review of the evidence of clozapine's anti-aggressive effects
Frogley, C. L., Taylor, D. M., Dickens, G. L., & Picchioni, M. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571100201x · Cited by 256 · see citing works
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242 · see citing works
Kane, J. M., Leucht, S., Carpenter, D. P., & Docherty, J. P. (2003) · PubMed · Cited by 234 · see citing works
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234 · see citing works
Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 216 · see citing works
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213 · see citing works
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 206 · see citing works
Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis
Fusar‐Poli, P., Cappucciati, M., Rutigliano, G., Heslin, M., Stahl, D. R., Brittenden, Z., Caverzasi, E., McGuire, P. K., & Carpenter, W. T. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw020 · Cited by 206 · see citing works
Chatterjee, A., Chakos, M., Koreen, A., Geisler, S., Sheitman, B., Woerner, M. G., Kane, J. M., Alvir, J. M., & Lieberman, J. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1724 · Cited by 194 · see citing works
Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates
Emsley, R. A., Rabinowitz, J., & Medori, R. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.013 · Cited by 193 · see citing works
Pathways to Aggression in Schizophrenia Affect Results of Treatment
Volavka, J., & Citrome, L. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr041 · Cited by 191 · see citing works
Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.1.122 · Cited by 183 · see citing works
Suzuki, T., Remington, G. J., Mulsant, B. H., Uchida, H., Rajji, T. K., Graff‐Guerrero, A., Mimura, M., & Mamo, D. C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.013 · Cited by 180 · see citing works
Self-citationHaloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
Ostinelli, E. G., Powney, M. J., Li, X., & Adams, C. E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009377.pub3 · Cited by 179 · see citing works
Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia
Kirson, N. Y., Weiden, P. J., Yermakov, S., Huang, W., Samuelson, T., Offord, S. J., Greenberg, P. E., & Wong, B. J. O. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08167 · Cited by 177 · see citing works
Violence in schizophrenia and bipolar disorder.
Volavka, J. (2013) · PubMed · Cited by 172 · see citing works
Kishimoto, T., Agarwal, V., Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 170 · see citing works
Efficacy of atypicalv.typical antipsychotics in the treatment of early psychosis: meta-analysis
Crossley, N. A., Constante, M., McGuire, P. K., & Power, P. (2010) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.109.066217 · Cited by 153 · see citing works
Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study
Caseiro, O., Pérez‐Iglesias, R., Mata, I. F., Martínez‐García, O., Pelayo‐Terán, J. M., Tabarés‐Seisdedos, R., de la Foz, V. O., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.05.001 · Cited by 150 · see citing works
Brain-imaging studies of treatment-resistant schizophrenia: a systematic review
Mouchlianitis, E. D., McCutcheon, R. A., & Howes, O. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00540-4 · Cited by 143 · see citing works
The semistructured BPRS interview and rating guide.
Rhoades, H. M., & Overall, J. E. (1988) · PubMed · Cited by 142 · see citing works
The evidence for illness progression after relapse in schizophrenia
Emsley, R. A., Chiliza, B., & Asmal, L. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.016 · Cited by 139 · see citing works
Attribution bias in ultra-high risk for psychosis and first-episode schizophrenia
An, S. K., Kang, J. I., Park, J. Y., Kim, K. R., Lee, S. Y., & Lee, E. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.01.025 · Cited by 135 · see citing works
Geographic and Clinical Variation in Clozapine Use in the United States
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201300180 · Cited by 130 · see citing works
Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials
Bollini, P., Pampallona, S., Orza, M. J., Adams, M. E., & Chalmers, T. C. (1994) · Psychological Medicine · doi:10.1017/s003329170002729x · Cited by 129 · see citing works
Depression in people with first-episode schizophrenia
Addington, D. E., Addington, J., & Patten, S. B. (1998) · The British Journal of Psychiatry · doi:10.1192/s0007125000297729 · Cited by 128 · see citing works
Self-citationOlanzapine and haloperidol in first episode psychosis: Two-year data
Green, A. I., Lieberman, J. A., Hamer, R. M., Glick, I. D., Gur, R. C., Kahn, R. S., McEvoy, J. P., Perkins, D. O., Rothschild, A. J., Sharma, T., et al. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.021 · Cited by 125 · see citing works
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 120 · see citing works
Acosta, F. J., Bosch, E., Sarmiento, G., Juanes, N., Caballero-Hidalgo, A., & Mayans, T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.007 · Cited by 119 · see citing works
The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults
(2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890426760 · Cited by 119 · see citing works
Remington, G., Kwon, J. S., COLLINS, A., Laporte, D., MANN, S., & Christensen, B. K. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.015 · Cited by 118 · see citing works
Self-citationMedication adherence in patients with schizophrenia
Phan, S. V. (2016) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636601 · Cited by 117 · see citing works
Treatment resistant schizophrenia and response to antipsychotics: A review
Suzuki, T., Remington, G. J., Mulsant, B. H., Rajji, T. K., Uchida, H., Graff‐Guerrero, A., & Mamo, D. C. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.016 · Cited by 115 · see citing works
Self-citationTreatment-resistant schizophrenic patients.
Kane, J. M. (1996) · PubMed · Cited by 114 · see citing works
Mouaffak, F., Tranulis, C., Gourévitch, R., Poirier, M. F., Douki, S., Oli, J.-P., Löo, H., & Gourion, D. (2006) · Clinical Neuropharmacology · doi:10.1097/00002826-200601000-00009 · Cited by 114 · see citing works
Benzodiazepines for psychosis-induced aggression or agitation
Zaman, H., Sampson, S. J., Beck, A., Sharma, T., Clay, F. J., Spyridi, S., Zhao, S., & Gillies, D. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003079.pub4 · Cited by 112 · see citing works
The “delayed onset” of antipsychotic action — an idea whose time has come and gone
Agid, O., Seeman, P., & Kapur, S. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0611 · Cited by 112 · see citing works
Robinson, D. G., Gallego, J. A., John, M., Petrides, G., Hassoun, Y., Zhang, J., Lopez, L. V., Braga, R. J., Sevy, S. M., Addington, J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv125 · Cited by 112 · see citing works
Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
Dold, M., & Leucht, S. (2014) · Evidence-Based Mental Health · doi:10.1136/eb-2014-101813 · Cited by 108 · see citing works
ATTRIBUTION BIAS IN ULTRA-HIGH RISK FOR PSYCHOSIS AND FIRST-EPISODE SCHIZOPHRENIA
An, S. K., Kang, J. I., Park, J. Y., Kim, K. R., Lee, S. Y., & Lee, E. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.235 · Cited by 101 · see citing works
Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification
Farooq, S., Agid, O., Foussias, G., & Remington, G. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt137 · Cited by 95 · see citing works
Self-citationDiagnostic change 10 years after a first episode of psychosis
Heslin, M., Lomas, B., Lappin, J., Donoghue, K., Reininghaus, U., Onyejiaka, A. N., Croudace, T. J., Jones, P. B., Murray, R. M., Fearon, P., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715000720 · Cited by 93 · see citing works
Antidepressants for people with both schizophrenia and depression
Whitehead, C., Moss, S., Cardno, A., Lewis, G., & Furtado, V. A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002305 · Cited by 92 · see citing works
Efficacy and safety of second-generation long-acting injections in schizophrenia
Fusar‐Poli, P., Kempton, M. J., & Rosenheck, R. A. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32835b091f · Cited by 89 · see citing works
Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics
Heres, S., Lambert, M., & Vauth, R. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)70001-x · Cited by 84 · see citing works
Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
Emsley, R. A., Oosthuizen, P., Koen, L., Niehaus, D. J. H., & Martínez, L. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827bfcc1 · Cited by 78 · see citing works
Alemán, A., & Kahn, R. S. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00097-9 · Cited by 73 · see citing works
Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study
Buckley, P. F., Schooler, N. R., GOFF, D. C., Hsiao, J., Kopelowicz, A. J., Lauriello, J., Manschreck, T. C., Mendelowitz, A. J., Miller, D. D., Severe, J. B., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu067 · Cited by 72 · see citing works
Trajectories and Antecedents of Treatment Response Over Time in Early-Episode Psychosis
Levine, S. Z., & Rabinowitz, J. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn120 · Cited by 72 · see citing works
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)
Powney, M. J., Adams, C. E., & Jones, H. G. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009377.pub2 · Cited by 72 · see citing works
Benzodiazepines for psychosis-induced aggression or agitation
Gillies, D. M., Sampson, S. J., Beck, A., & Rathbone, J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003079.pub3 · Cited by 69 · see citing works
Clozapine’s Role in the Treatment of First-Episode Schizophrenia
Remington, G. J., Agid, O., Foussias, G., Hahn, M., Rao, N. P., & Sinyor, M. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12060778 · Cited by 63 · see citing works
Self-citationShould long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review
Taylor, M., & Ng, K. Y. B. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412470010 · Cited by 62 · see citing works
The psychopharmacology of violence: making sensible decisions
Citrome, L., & Volavka, J. (2014) · CNS Spectrums · doi:10.1017/s1092852914000054 · Cited by 61 · see citing works
Where to Position Clozapine: Re-Examining the Evidence
Agid, O., Foussias, G., Singh, S., & Remington, G. J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501007 · Cited by 56 · see citing works
Self-citationLong-Acting Injectable Antipsychotics: Evidence of Effectiveness and Use
Manchanda, R., Chue, P. S., MALLA, A. K., Tibbo, P. G., Roy, M., Williams, R. L., Iyer, S. N., Lutgens, D., & Banks, N. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s02 · Cited by 55 · see citing works
Muscatello, M. R. A., Bruno, A., Fazio, P. D., Segura‐Garcìa, C., Pandolfo, G., & Zoccali, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.956082 · Cited by 54 · see citing works
Lee, J., Takeuchi, H., Fervaha, G., Sin, G. L., Foussias, G., Agid, O., Farooq, S., & Remington, G. J. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506001107 · Cited by 54 · see citing works
Self-citationDepression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 52 · see citing works
Boaz, T. L., Becker, M. A., Andel, R., Dorn, R. A. V., Choi, J. C., & Sikirica, M. V. (2013) · Psychiatric Services · doi:10.1176/appi.ps.003382012 · Cited by 51 · see citing works
Long-Acting Injectable Antipsychotics: Recommendations for Clinicians
MALLA, A. K., Tibbo, P. G., Chue, P. S., Lévy, E., Manchanda, R., Teehan, M. D., Williams, R., Iyer, S. N., & Roy, M. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/088740341305805s05 · Cited by 49 · see citing works
Self-citationCrosby, T. D. L. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.04.016 · Cited by 41 · see citing works
Psychopharmacology of Aggression in Schizophrenia
Buckley, P. F., Citrome, L., Nichita, E. C., & Vitacco, M. J. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr104 · Cited by 41 · see citing works
Victoroff, J., Coburn, K. L., Reeve, A., Sampson, S. M., & Shillcutt, S. D. (2014) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.13110335 · Cited by 40 · see citing works
Antipsychotic medication for early episode schizophrenia
Bola, J. R., Kao, D., Soydan, H., & Adams, C. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006374.pub2 · Cited by 40 · see citing works
Sustained-Release, Extended-Release, and Other Time-Release Formulations in Neuropsychiatry
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15f10219 · Cited by 39 · see citing works
Alphs, L. D., Schooler, N. R., & Lauriello, J. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.024 · Cited by 38 · see citing works
The neurobiology of relapse in schizophrenia
Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38 · see citing works
Self-citationRandomized Controlled Trials of Add-On Antidepressants in Schizophrenia
Terevnikov, V., Joffe, G., & Stenberg, J. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv049 · Cited by 37 · see citing works
Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., de Millas, W., Maier, W., Ruhrmann, S., Falkai, P., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.024 · Cited by 36 · see citing works
Bossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33 · see citing works
Addington, D. E., Mohamed, S., Rosenheck, R. A., Thomas, S., Stroup, T. S., McEvoy, J. P., Swartz, M. S., & Lieberman, J. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05258gre · Cited by 33 · see citing works
Self-citationThe pharmacological management of violence in schizophrenia: a structured review
Topiwala, A., & Fazel, S. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.180 · Cited by 32 · see citing works
Al-Dhaher, Z., Kapoor, S., Saito, E., Krakower, S., David, L., Ake, T., Kane, J. M., Correll, C. U., & Carbon, M. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0141 · Cited by 24 · see citing works
Antipsychotic Medication for Early-Episode Schizophrenia
Bola, J. R., Kao, D., & Soydan, H. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr167 · Cited by 21 · see citing works
Belli, H., & Ural, C. (2012) · West Indian Medical Journal · doi:10.7727/wimj.2011.028 · Cited by 20 · see citing works
Canadian Journal of Psychiatry: New Editor and New Policies
Paris, J. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000101 · Cited by 20 · see citing works
2012 CCNP Innovations Award Paper: Antipsychotic dosing: found in translation
Remington, G. J., Fervaha, G., Foussias, G., Agid, O., & Turrone, P. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130191 · Cited by 13 · see citing works
Self-citationMustafa, F. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827a813b · Cited by 10 · see citing works
Augmenting Clozapine Response in Treatment-Resistant Schizophrenia
Remington, G. J. (2010) · Advances in biological psychiatry · doi:10.1159/000319813 · Cited by 9 · see citing works
Self-citationAntipsychotic Dosing: Still a Work in Progress
Remington, G. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10030302 · Cited by 9 · see citing works
Self-citationManaging pathologic aggression in people with psychotic disorders
Bourget, D., & Labelle, A. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110174 · Cited by 4 · see citing works
Flagged first, then by citations
2 of the 118 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 607 · see citing works
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 153 · see citing works
Correll, C. U., Newcomer, J. W., Silverman, B. L., DiPetrillo, L., Graham, C. E., Jiang, Y., Du, Y., Simmons, A., Hopkinson, C., McDonnell, D., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19121279 · Cited by 120 · see citing works
Rosson, S., de Filippis, R., Croatto, G., Collantoni, E., Pallottino, S., Guinart, D., Brunoni, A. R., Dell’Osso, B. M., Pigato, G., Hyde, J., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104743 · Cited by 112 · see citing works
Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110 · see citing works
Dempster, K., Jeon, P., Mackinley, M., Williamson, P., Théberge, J., & Palaniyappan, L. K. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0704-x · Cited by 94 · see citing works
Emerging evidence for astrocyte dysfunction in schizophrenia
Figueiredo, E. C. D. O., Calì, C., Petrelli, F., & Bezzi, P. (2022) · Glia · doi:10.1002/glia.24221 · Cited by 85 · see citing works
Alterations of Astrocytes in the Context of Schizophrenic Dementia
Tarasov, V. V., Svistunov, A. А., Chubarev, V. N., Sologova, S. S., Мухортова, П. А., Levushkin, D., Somasundaram, S. G., Kirkland, C. E., Бачурин, С. О., & Aliev, G. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01612 · Cited by 84 · see citing works
A Focused Review of the Metabolic Side-Effects of Clozapine
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 92 · see citing works
Self-citationOstuzzi, G., Bertolini, F., Giovane, C. D., Tedeschi, F., Bovo, C., Gastaldon, C., Nosè, M., Ogheri, F., Papola, D., Purgato, M., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20071120 · Cited by 83 · see citing works
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79 · see citing works
Clozapine haematological monitoring for neutropenia: a global perspective
Oloyede, E., Blackman, G., Whiskey, E., Bachmann, C., Dzahini, O., Shergill, S. S., Taylor, D. M., McGuire, P. K., & MacCabe, J. H. (2022) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602200066x · Cited by 75 · see citing works
Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects
Orsolini, L., Pompili, S., & Volpe, U. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175040 · Cited by 73 · see citing works
Polese, D., Fornaro, M., Palermo, M., Luca, V. D., & de Bartolomeis, A. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00210 · Cited by 70 · see citing works
Fond, G. B., Godin, O., Boyer, L., Berna, F. S., Andrianarisoa, M., Coulon, N., Brunel, L., Bulzacka, E., Aouizerate, B., Capdevielle, D., et al. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0908-0 · Cited by 70 · see citing works
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.013 · Cited by 62 · see citing works
Abidi, S., Mian, I. A., Ortega, I., Lecomte, T., Raedler, T. J., Jackson, K., Jackson, K., Pringsheim, T. M., & Addington, D. E. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720197 · Cited by 63 · see citing works
Self-citationDelayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern
John, A. P., Ko, E. K. F., & Dominic, A. (2018) · The Canadian Journal of Psychiatry · doi:10.1177/0706743718772522 · Cited by 60 · see citing works
Brexpiprazole: A Review in Schizophrenia
Frampton, J. E. (2019) · Drugs · doi:10.1007/s40265-019-1052-5 · Cited by 57 · see citing works
Campana, M., Falkai, P., Siskind, D. J., Hasan, A., & Wagner, E. M. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.002 · Cited by 56 · see citing works
Takaesu, Y., Watanabe, K., Numata, S., Iwata, M., Kudo, N., Oishi, S., Takizawa, T., Nemoto, K., Yasuda, Y., Tagata, H., et al. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12911 · Cited by 51 · see citing works
Lian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13202 · Cited by 47 · see citing works
Self-citationLiu, Y., Xu, J. L., Fang, K., Xu, Y., Gao, J., Zhou, C., Tang, X., Fang, X., Chen, J., Xie, C., et al. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320982720 · Cited by 47 · see citing works
Faden, J., & Citrome, L. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.008 · Cited by 42 · see citing works
State of the Science: The Hierarchical Taxonomy of Psychopathology (HiTOP)
Cicero, D. C., Ruggero, C. J., Balling, C. E., Bottera, A. R., Cheli, S., Elkrief, L., Forbush, K. T., Hopwood, C. J., Jonas, K. G., Jutras‐Aswad, D., et al. (2024) · Behavior Therapy · doi:10.1016/j.beth.2024.05.001 · Cited by 42 · see citing works
Matsui, K., Tokumasu, T., Takekita, Y., Inada, K., Kanazawa, T., Kishimoto, T., Takasu, S., Tani, H., Tarutani, S., Hashimoto, N., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.030 · Cited by 41 · see citing works
Chrétien, B., Lelong‐Boulouard, V., Chantepie, S., Sassier, M., Bertho, M., Brazo, P., Humbert, X., Alexandre, J., Fédrizzi, S., & Dolladille, C. (2020) · Psychological Medicine · doi:10.1017/s0033291720000161 · Cited by 39 · see citing works
Adipose tissue as a target for second-generation (atypical) antipsychotics: A molecular view
Ferreira, V., Grajales, D., & Valverde, Á. M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.158534 · Cited by 39 · see citing works
Li, K. J., Greenstein, A. P., & DeLisi, L. E. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000403 · Cited by 37 · see citing works
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R., & Muscatello, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 43 · see citing works
Hui, C. L. M., Lam, B. S. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., Suen, Y. N., & Chen, E. Y. H. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1613965 · Cited by 36 · see citing works
Shimomura, Y., Kikuchi, Y., Suzuki, T., Uchida, H., Mimura, M., & Takeuchi, H. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.040 · Cited by 34 · see citing works
Gäebel, W., Stricker, J. H., & Riesbeck, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.049 · Cited by 35 · see citing works
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33 · see citing works
Potentially fatal outcomes associated with clozapine
Li, K. J., Gurrera, R. J., & DeLisi, L. E. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.02.058 · Cited by 32 · see citing works
Goldstone, L. W., DiPaula, B. A., Werremeyer, A. B., Botts, S. R., Hepburn, B. M., Liu, H. Y., Duckworth, K., Young, A. S., & Kelly, D. L. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000066 · Cited by 32 · see citing works
Ochi, S., Tagata, H., Hasegawa, N., Yasui‐Furukori, N., Iga, J., Kashiwagi, H., Kodaka, F., Komatsu, H., Tsuboi, T., Tokutani, A., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac036 · Cited by 29 · see citing works
Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0565-x · Cited by 29 · see citing works
Zadeh, E. M., Bayanati, S., Ziafat, K., Rezaei, F., Mesgarpour, B., & Akhondzadeh, S. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120909416 · Cited by 29 · see citing works
Ercis, M., Sánchez-Ruiz, J. A., Webb, L. M., Solares‐Bravo, M., Betcher, H. K., Moore, K. M., Frye, M. A., Veldić, M., & Özerdem, A. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.02.038 · Cited by 28 · see citing works
Pan, Y., Dempster, K., Jeon, P., Théberge, J., Khan, A. R., & Palaniyappan, L. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200167 · Cited by 28 · see citing works
Ferreira, V., Folgueira, C., Guillén, M., Zubiaur, P., Navares, M., Sarsenbayeva, A., López-Larrubia, P., Eriksson, J. W., Pereira, M. J., Abad‐Santos, F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155335 · Cited by 29 · see citing works
Ismail, D., Tounsi, K., Zolezzi, M., & Eltorki, Y. H. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.12.011 · Cited by 27 · see citing works
Hatta, K., Hasegawa, H., Imai, A., Sudo, Y., Morikawa, F., Katayama, S., Watanabe, H., Ishizuka, T., Nakamura, M., Misawa, F., et al. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.02.005 · Cited by 26 · see citing works
Ghabrash, M. F., Coronado‐Montoya, S., Aoun, J., Gagné, A.-A., Mansour, F., Ouellet‐Plamondon, C., Trépanier, A., & Jutras‐Aswad, D. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112890 · Cited by 26 · see citing works
Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients
Ayani, N., Morimoto, T., Sakuma, M., Kikuchi, T., Watanabe, K., & Narumoto, J. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001416 · Cited by 26 · see citing works
Schizophrenia: Antipsychotics and drug development
Remington, G. J., Hahn, M., Agarwal, S. M., Chintoh, A. F., & Agid, O. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113507 · Cited by 26 · see citing works
Self-citationDey, A., Dempster, K., Mackinley, M., Jeon, P., Das, T. K., KHAN, A. R., Gati, J. S., & Palaniyappan, L. K. (2021) · Schizophrenia · doi:10.1038/s41537-020-00130-3 · Cited by 25 · see citing works
Brown, B., Turkoz, I., Mancevski, B., & Mathews, M. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12868 · Cited by 23 · see citing works
Lin, C., Chen, Y.-M., & Lane, H. (2019) · Current Drug Targets · doi:10.2174/1389450120666191011163539 · Cited by 23 · see citing works
Kim, D. D., Barr, A. M., Lian, L., Yuen, J. W. Y., Fredrikson, D. H., Honer, W. G., Thornton, A. E., & Procyshyn, R. M. (2021) · Schizophrenia · doi:10.1038/s41537-021-00158-z · Cited by 23 · see citing works
Self-citationSuetani, S., Dark, F. L., Every‐Palmer, S., Galletly, C. A., O'Donoghue, B. N., Halstead, S., Keating, D., Korman, N., Lappin, J., Lawn, S., et al. (2026) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251406058 · Cited by 23 · see citing works
Nasyrova, R., Khasanova, A. K., Altynbekov, K. S., Asadullin, A., Markina, E. A., Gayduk, A., Shipulin, G., Petrova, M. M., & Shnayder, N. (2022) · Nutrients · doi:10.3390/nu14235142 · Cited by 16 · see citing works
Hasegawa, N., Yasuda, Y., Yasui‐Furukori, N., Yamada, H., Hori, H., Ichihashi, K., Takaesu, Y., Iida, H., Muraoka, H., Kodaka, F., et al. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13578 · Cited by 22 · see citing works
Asmundson, G., Blackstock, C., Bourque, M. C., Brimacombe, G., Crawford, A., Deacon, S., McMullen, K., McGrath, P., Mushquash, C., Stewart, S., et al. (2020) · FACETS · doi:10.1139/facets-2020-0082 · Cited by 23 · see citing works
Calzavara‐Pinton, I., Nibbio, G., Barlati, S., Bertoni, L., Necchini, N., Zardini, D., Baglioni, A., Paolini, S., Poddighe, L., Bulgari, V., et al. (2024) · Brain Sciences · doi:10.3390/brainsci14080791 · Cited by 23 · see citing works
Yamada, H., Motoyama, M., Hasegawa, N., Miura, K., Matsumoto, J., Ohi, K., Yasui‐Furukori, N., Numata, S., Takeshima, M., Sugiyama, N., et al. (2022) · BJPsych Open · doi:10.1192/bjo.2022.44 · Cited by 21 · see citing works
Yasui‐Furukori, N., Muraoka, H., Hasegawa, N., Ochi, S., Numata, S., Hori, H., Hishimoto, A., Onitsuka, T., Ohi, K., Hashimoto, N., et al. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12218 · Cited by 21 · see citing works
Brodeur, S., Vanasse, A., Courteau, J., Courteau, M., Stip, É., Fleury, M., LESAGE, A. D., Demers, M., & Roy, M. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13411 · Cited by 21 · see citing works
Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
Smessaert, S., Detraux, J., Desplenter, S., & Binder, M. D. (2024) · CNS Drugs · doi:10.1007/s40263-023-01054-z · Cited by 20 · see citing works
Vellucci, L., Mazza, B., Barone, A., Nasti, A., Simone, G. D., Iasevoli, F., & de Bartolomeis, A. (2025) · Biomolecules · doi:10.3390/biom15050615 · Cited by 22 · see citing works
Puranen, A., Koponen, M., Lähteenvuo, M., Tanskanen, A. J., Tiihonen, J., & Taipale, H. T. (2023) · Schizophrenia · doi:10.1038/s41537-023-00364-x · Cited by 18 · see citing works
Tréhout, M., Zhang, N., Blouet, M., Borha, A., & Dollfus, S. (2018) · Neuropsychobiology · doi:10.1159/000494695 · Cited by 18 · see citing works
Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?
Pae, C. (2020) · Chonnam Medical Journal · doi:10.4068/cmj.2020.56.3.157 · Cited by 18 · see citing works
Pae, C., Han, C., Bahk, W., Lee, S.-J., Patkar, A. A., & Masand, P. S. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.434 · Cited by 18 · see citing works
Zolk, O., Greiner, T., Schneider, M., Heinze, M., Dahling, V., Ramin, T., Grohmann, R., Bleich, S., Zindler, T., Toto, S., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.2011403 · Cited by 17 · see citing works
Kang, D., Lu, J., Liu, W., Shao, P., & Wu, R. (2022) · Schizophrenia · doi:10.1038/s41537-022-00211-5 · Cited by 17 · see citing works
Agid, O., Remington, G. J., Fung, C., Nightingale, N., Duclos, M., & Anger, G. J. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211055413 · Cited by 17 · see citing works
Self-citationLippi, M., Fanelli, G., Fabbri, C., Ronchi, D. D., & Serretti, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000417 · Cited by 17 · see citing works
Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.
(2018) · Europe PMC (PubMed Central) · Cited by 17 · see citing works
Li, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16 · see citing works
Kane, J. M., Schoretsanitis, G., Rubio, J. M., & Correll, C. U. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.035 · Cited by 16 · see citing works
Glutamate modulators for treatment of schizophrenia
Zhand, N., Attwood, D. G., & Harvey, P. D. (2019) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2019.02.001 · Cited by 16 · see citing works
Rabkin, S. W., & Tang, J. K. K. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220211094910 · Cited by 15 · see citing works
Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
Kamei, H. (2022) · Medicina · doi:10.3390/medicina58111584 · Cited by 15 · see citing works
Dopamine partial agonists: a discrete class of antipsychotics
Taylor, D. M., Chithiramohan, R. N., Grewal, J., Gupta, A., Hansen, L. K., Reynolds, G. P., & Pappa, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2151473 · Cited by 15 · see citing works
Tsimpili, H., & Zoidis, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030369 · Cited by 15 · see citing works
Alphs, L. D., Brown, B., Turkoz, I., Baker, P. C., Fu, D., & Nuechterlein, K. H. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.02.019 · Cited by 15 · see citing works
Clozapine-Related Myocarditis and Rechallenge
Noël, M.-C., Powell, V., Burton, L., Panda, R., & Remington, G. J. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001062 · Cited by 15 · see citing works
Self-citationBarriers and facilitators of exploiting the potential of value-added medicines
Petykó, Z. I., Inotai, A., Holtorf, A., Brixner, D. I., & Kaló, Z. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1758558 · Cited by 15 · see citing works
He, X., Sun, T., Wang, L., & Jiang, X. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122499 · Cited by 15 · see citing works
Oedegaard, C., Ruano, A. L., Blindheim, A., Veseth, M., Stige, B., Davidson, L., & Engebretsen, I. (2022) · International Journal of Mental Health Systems · doi:10.1186/s13033-022-00529-8 · Cited by 7 · see citing works
Lunghi, C., Rochette, L., Massamba, V. K., Tardif, I., Ouali, A., & Sirois, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1080073 · Cited by 15 · see citing works
An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia
Neufeld, N. H., & Blumberger, D. M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250068 · Cited by 14 · see citing works
Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management
Kelly, D. L., & Love, R. C. (2019) · Mental Health Clinician · doi:10.9740/mhc.2019.03.064 · Cited by 14 · see citing works
Woo, Y. S., Yoon, B.-H., Jeon, B.-H., Seo, J. S., Nam, B., Lee, S.-Y., Jae, Y. M., Jang, S., Eun, H. J., Won, S., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.3.423 · Cited by 14 · see citing works
Kimura, H., Kanahara, N., & Iyo, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113126 · Cited by 14 · see citing works
Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies
Wu, B., Wu, L., He, Y., Yin, Z., & Deng, L. (2021) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2021.1934859 · Cited by 14 · see citing works
Paliperidone palmitate once‐every‐3‐months in adults with early illness schizophrenia
Lynum, K. S. B., Turkoz, I., & Kim, E. (2018) · Early Intervention in Psychiatry · doi:10.1111/eip.12685 · Cited by 14 · see citing works
Clinically Relevant Anti-Neuronal Cell Surface Antibodies in Schizophrenia Spectrum Disorders
Colijn, M. A., & Ismail, Z. (2019) · Neuropsychobiology · doi:10.1159/000499714 · Cited by 14 · see citing works
Self-citationBorrelli, E. P., Lee, E. Y., & Caffrey, A. R. (2020) · Mental Health Clinician · doi:10.9740/mhc.2020.05.070 · Cited by 14 · see citing works
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13 · see citing works
“51 Unfortunately, one limitation of using clinical markers to inform subsequent treatment decisions is that they rely on trial and error, which means longer time experiencing symptoms until the optimal treatment is identified.”
BackgroundPrescribing Trends for the Same Patients with Schizophrenia Over 20 Years
Yasui‐Furukori, N., Kawamata, Y., Sasaki, T., Yokoyama, S., Okayasu, H., Shinozaki, M., Takeuchi, Y., Sato, A., Takaaki, I., Komahashi‐Sasaki, H., et al. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s390482 · Cited by 13 · see citing works
Rubio, J. M., Guinart, D., Kane, J. M., & Correll, C. U. (2023) · CNS Drugs · doi:10.1007/s40263-023-01009-4 · Cited by 13 · see citing works
Patterns of prescription of antipsychotics in Qatar
Ouanes, S., Becetti, I., Ghuloum, S., Hammoudeh, S., Shehata, M., Ghabrash, H., Yehya, A., Lawati, H. J. A., AlFakhri, N., Iram, H., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241986 · Cited by 12 · see citing works
García‐Portilla, M. P., Ruiz, A. B., Robina, F. G., Dorado, M. G., & Rengel, P. M. L. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.2023496 · Cited by 12 · see citing works
Ferreira, V., Folgueira, C., García‐Altares, M., Guillén, M., Ruíz-Rosario, M., Nunzio, G. D., García‐Martinez, I., Alén, R., Bookmeyer, C., Jones, J. G., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102741 · Cited by 12 · see citing works
Monteleone, P., Amore, M., Cabassi, A., Clerici, M., Fagiolini, A. M., Girardi, P., Jannini, E. A., Maina, G., Rossi, A., Vita, A., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00842 · Cited by 12 · see citing works
Schizophrenia Psychosis in Women
Seeman, M. (2020) · Women · doi:10.3390/women1010001 · Cited by 11 · see citing works
Sockalingam, S., Kirvan, A., Pereira, C., Rajaratnam, T., Elzein, Y., Serhal, E., & Crawford, A. (2021) · Telemedicine journal and e-health · doi:10.1089/tmj.2021.0122 · Cited by 12 · see citing works
- Authors
- Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University of Calgary (CA)
- University of British Columbia (CA)
- Dalhousie University (CA)
- Corresponding author
- Remington, Gary
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2017-07-13
- Volume
- 62
- Issue
- 9
- Pages
- 604-616
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- PMC
- PMC5593252
- OpenAlex
- W2737472140
- Cited by
- 332
- References
- 118
- Citations by year
- 2026: 29 · 2025: 32 · 2024: 46 · 2023: 38 · 2022: 66 · 2021: 56 · 2020: 23 · 2019: 28 · 2018: 13 · 2017: 1
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Canadian Journal of Psychiatry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hotchkiss Brain Institute, University of Calgary
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- schizophrenia, pharmacotherapy, adults, first-episode schizophrenia, acute exacerbation, relapse prevention, maintenance therapy, treatment-resistant schizophrenia, clozapine-resistant schizophrenia, antipsychotic drugs, symptom domains, evidence-based recommendations
- MeSH terms
- Adult, Canada, Humans, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
